PMID- 31804340
OWN - NLM
STAT- MEDLINE
DCOM- 20191219
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 49
DP  - 2019 Dec
TI  - Does synbiotic supplementation affect body weight, body mass index, and 
      high-sensitivity C-reactive protein levels in patients with type 2 diabetes? 
      Protocol for a systematic review and meta-analysis.
PG  - e18197
LID - 10.1097/MD.0000000000018197 [doi]
LID - e18197
AB  - BACKGROUND: The number of patients with type 2 diabetes mellitus (T2DM) is 
      surging currently. Synbiotic as a supplement based on gut microbiota may be 
      beneficial to improve the metabolism of T2DM. However, the results of clinical 
      studies show that the role of synbiotic in weight management in patients with 
      T2DM is controversial. In this context, we have formulated this protocol. The 
      study will evaluate the effects of synbiotic supplementation on body weight, body 
      mass index (BMI), and high-sensitivity C-reactive protein (hs-CRP) levels in 
      patients with T2DM. METHODS: The electronic databases PubMed, Embase, and the 
      Cochrane Library will be searched for relevant literature from inception. 
      Literature search, data extraction, and methodological quality assessment will be 
      carried out independently by two researchers. All randomized controlled trials 
      (RCTs) that met the criteria will be included. A meta-analysis will be conducted 
      using weighted mean difference (WMD) and 95% confidence interval (CI) as effect 
      measures. RESULTS: This systematic review and meta-analysis will mainly assess 
      the effects of synbiotic supplementation on body weight and BMI in T2DM patients. 
      Secondary outcome indicators will include hs-CRP. CONCLUSION: This systematic 
      review and meta-analysis will quantify the value of synbiotic supplement in 
      weight management of patients with T2DM through a comprehensive evaluation of the 
      current clinical evidence, so as to provide a basis for clinical application. 
      PROSPERO REGISTRATION NUMBER: CRD42019132974.
FAU - Chen, Yuan
AU  - Chen Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
FAU - Li, Zhenhua
AU  - Li Z
AD  - Department of Obstetrics and Gynecology, Qufu Hospital of Traditional Chinese 
      Medicine, Qufu, Shandong, China.
FAU - Yang, Maoyi
AU  - Yang M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
FAU - Shui, Jiacheng
AU  - Shui J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
FAU - Yue, Rensong
AU  - Yue R
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - *Body Mass Index
MH  - Body Weight/*drug effects
MH  - C-Reactive Protein/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Synbiotics/*administration & dosage
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC6919432
COIS- The authors declare no conflicts of interest.
EDAT- 2019/12/06 06:00
MHDA- 2019/12/20 06:00
PMCR- 2019/12/10
CRDT- 2019/12/06 06:00
PHST- 2019/12/06 06:00 [entrez]
PHST- 2019/12/06 06:00 [pubmed]
PHST- 2019/12/20 06:00 [medline]
PHST- 2019/12/10 00:00 [pmc-release]
AID - 00005792-201912060-00039 [pii]
AID - MD-D-19-08343 [pii]
AID - 10.1097/MD.0000000000018197 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Dec;98(49):e18197. doi: 10.1097/MD.0000000000018197.